Long-term treatment with mesalazine in patients with symptomatic uncomplicated diverticular disease

Internal and Emergency Medicine

Volumn 7, Issue 2, 2012, Pages 133-137

  Gatta, Luigi ^a,b   Di Mario, Francesco ^b   Curlo, Margherita ^b   Vaira, Dino ^c   Pilotto, Alberto ^d   Lucarini, Paolo ^a   Lera, Maurizio ^a   Enkleda, Kajo ^f   Franzé, Angelo ^e   Scarpignato, Carmelo ^b  

^a Versilia Hospital   (Italy)

^b UNIVERSITY OF PARMA   (Italy)

^c UNIVERSITY OF BOLOGNA   (Italy)

^d CASA SOLLIEVO DELLA SOFFERENZA HOSPITAL   (Italy)

^e Parma Hospital   (Italy)

^f UNIVERSITY OF BOLOGNA   (Italy)

Author keywords

Colon; Mesalamine; Symptom assessment

Indexed keywords

MESALAZINE; NONSTEROID ANTIINFLAMMATORY AGENT;

AGED; ARTICLE; CLINICAL TRIAL; COLON DIVERTICULOSIS; COMPARATIVE STUDY; CONFIDENCE INTERVAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE RESPONSE; DRUG ADMINISTRATION; FEMALE; FOLLOW UP; HOSPITALIZATION; HUMAN; KAPLAN MEIER METHOD; LONG TERM CARE; MALE; MIDDLE AGED; MORTALITY; MULTICENTER STUDY; NEEDLE BIOPSY; NONPARAMETRIC TEST; ORAL DRUG ADMINISTRATION; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; RECURRENT DISEASE; RISK ASSESSMENT; SURVIVAL RATE; TREATMENT OUTCOME;

ADMINISTRATION, ORAL; AGED; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; BIOPSY, NEEDLE; CONFIDENCE INTERVALS; DIVERTICULITIS, COLONIC; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; FEMALE; FOLLOW-UP STUDIES; HUMANS; KAPLAN-MEIER ESTIMATE; LONG-TERM CARE; MALE; MESALAMINE; MIDDLE AGED; PROSPECTIVE STUDIES; RECURRENCE; RISK ASSESSMENT; SEVERITY OF ILLNESS INDEX; STATISTICS, NONPARAMETRIC; SURVIVAL RATE; TREATMENT OUTCOME;

EID: 84859436687     PISSN: 18280447     EISSN: 19709366     Source Type: Journal    
DOI: 10.1007/s11739-011-0509-7     Document Type: Article

References (34)

1. Sheth AA, Longo W, Floch MH (2008) Diverticular disease and diverticulitis. Am J Gastroenterol 103: 1550-1556.
2. Parra-Blanco A (2006) Colonic diverticular disease: pathophysiology and clinical picture. Digestion 73(Suppl. 1): 47-57.
3. Stollman N, Raskin JB (2004) Diverticular disease of the colon. Lancet 363: 631-639.
4. Brodribb AJ (1977) Treatment of symptomatic diverticular disease with a high-fibre diet. Lancet 1: 664-666.
5. Ornstein MH, Littlewood ER, Baird IM et al (1981) Are fibre supplements really necessary in diverticular disease of the colon? A controlled clinical trial. Br Med J (Clin Res Ed) 282: 1353-1356.
6. Weinreich J (1982) Treatment of diverticular disease. Scand J Gastroenterol Suppl 79: 128-129.
7. Soltoft J, Krag B, Gudmand-Hoyer E et al (1976) A double-blind trial of the effect of wheat bran on symptoms of irritable bowel syndrome. Lancet 1: 270-272.
8. Hodgson WJ (1977) The placebo effect. Is it important in diverticular disease? Am J Gastroenterol 67: 157-162.
9. Longstreth GF, Fox DD, Youkeles L et al (1981) Psyllium therapy in the irritable bowel syndrome. A double-blind trial. Ann Intern Med 95: 53-56.
10. Floch MH (2006) A hypothesis: is diverticulitis a type of inflammatory bowel disease? J Clin Gastroeneterol 40(Suppl. 3): S121-S125.
11. Peppercorn MA (2004) The overlap of inflammatory bowel disease and diverticular disease. J Clin Gastroenterol 38(Suppl. 5): S8-S10.
12. Nielsen OH, Munck LK (2007) Drug Insight: aminosalicylates for the treatment of IBD. Nat Clin Pract Gastroenterol Hepatol 4: 160-170.
13. Gatta L, Vakil N, Vaira D et al (2010) Efficacy of 5-ASA in the treatment of colonic diverticular disease. J Clin Gastroenterol 44: 113-119.
14. Newcombe R, Altman D (2000) Proportion and their differences. In: Altman D, Machin D, Trevor N, Gardner M (eds) Statistics with confidences. BMJ Books, London, pp 45-56.
15. Rajendra S, Ho JJ (2005) Colonic diverticular disease in a multiracial Asian patient population has an ethnic predilection. Eur J Gastroenterol Hepatol 17: 871-875.
16. Fox JM, Stollman NH (2006) Diverticular Disease of the colon. In: Feldam M, Friedman LA, Brandt LJ (eds) Gastrointestinal and liver disease, 8th edn. Saunders Elsevier, Philadelphia.
17. Nakaji S, Danjo K, Munakata A, Sugawara K, MacAuley D, Kernohan G, Baxter D (2002) Comparison of etiology of right-sided diverticula in Japan with that of left-sided diverticula in the West. Int J Colorectal Dis 17: 365-373.
18. Takano M, Yamada K, Sato K (2005) An analysis of the development of colonic diverticulosis in the Japanese. Dis Colon Rectum 48: 2111-2116.
19. Kang J, Melville D, Maxwell JD (2004) Epidemiology and management of diverticular disease of the colon. Drugs Aging 21: 211-228.
20. American Gastroenterological Association (2001) The burden of gastrointestinal disease. American Gastroenterological Association, Bethesda.
21. Chautems RC, Ambrosetti P, Ludwing A, Mermillod B, Morel P, Soravia C (2002) Long-term follow-up after first acute episode of sigmoid diverticulitis: is surgery mandatory? A prospective study of 118 patients. Dis Colon Rectum 45: 962-966.
22. Salem TA, Molloy RG, O'Dwyer PJ (2007) Prospective five-year follow-up study of patients with symptomatic uncomplicated diverticular disease. Dis Colon Rectum 50: 1460-1464.
23. Makapugay LM, Dean PJ (1996) Diverticular disease-associated chronic colitis. Am J Surg Pathol 20: 94-102.
24. Sheperd NA (1996) Diverticular disease and chronic idiopathic inflammatory bowel disease: associations and masquerades. Gut 38: 801-802.
25. Rogler G, Andus T (1998) Cytokines in inflammatory bowel disease. World J Surg 22: 382-389.
26. Izzo AA, Mascolo N, Capasso F (1998) Nitric oxide as a modulator of intestinal water and electrolyte transport. Dig Dis Sci 43: 1605-1620.
27. Tursi A Diverticular disease of the colon 2004 363: 1397-1398.
28. Desreumaux P, Ghosh S (2006) Review article: mode of action and delivery of 5-aminosalicylic acid-new evidence. Aliment Pharmacol Ther 24(Suppl 1): 2-9.
29. Tursi A, Brandimarte G, Elisei W et al (2008) Effect of mesalazine on epithelial cell proliferation in colonic diverticular disease. Dig Liver Dis 40: 737-742.
30. Trespi E, Colla G, Panizza P et al (1999) Ruolo terapeutico e profilattico della mesalazina (5-ASA) nella malattia diverticolare sintomatica del crasso. Minerva Gastroenterol Dietol 45: 245-252.
31. Tursi A, Brandimarte G, Giorgetti GM et al (2006) Mesalazine and/or Lactobacillus casei in preventing recurrence of symptomatic uncomplicated diverticular disease of the colon: a prospective, randomized, open-label study. J Clin Gastroenterol 40: 312-316.
32. Comparato G, Fanigliulo L, Cavallaro LG et al (2007) Prevention of complications and symptomatic recurrences in diverticular disease with mesalazine: a 12-month follow-up. Dig Dis Sci 52: 2934-2941.
33. Mechanistic randomized controlled trial of mesalazine in symptomatic diverticular disease. Clinical. Trials. gov. Identifier (http://www. clinicaltrials. gov): NCT00663247. Principal Investigator: Spiller RC, Nottingham University Hospital, UK.
34. A phase III, randomised double blind dose response stratified placebo controlled study of evaluating the safety and efficacy of SPD476 versus placebo over 104 weeks in the prevention of recurrence of diverticulitis (PREVENT 2). Clinical. Trials. gov. Identifier (http://www. clinicaltrials. gov): NCT00545103. Principal Investigator: Raskin JB, University of Miami Miller School of Medicine, USA.